The effectiveness of the combination of lenvatinib and everolimus in metastatic renal cell carcinoma in patients with resistance to targeted treatment in real clinical practice

R. Rakhimov, A. V. Sultanbaev, K. Menshikov, A. Nasretdinov, S. Musin, O. Lipatov, V. A. Suravatkin
{"title":"The effectiveness of the combination of lenvatinib and everolimus in metastatic renal cell carcinoma in patients with resistance to targeted treatment in real clinical practice","authors":"R. Rakhimov, A. V. Sultanbaev, K. Menshikov, A. Nasretdinov, S. Musin, O. Lipatov, V. A. Suravatkin","doi":"10.33667/2078-5631-2024-7-18-25","DOIUrl":null,"url":null,"abstract":"Every year, 400,000 new cases of renal cell carcinoma (RCC) and 175,000 deaths are registered worldwide. Currently available advanced treatments for RCC have less toxicity than previously used therapeutic agents, but drug resistance remains a clinically significant problem. Drug resistance occurs as a result of angiogenic transition through activation of pathways that do not depend on VEGF targets of most first-line treatments. Lenvatinib with everolimus can fight resistance to increase both progression-free survival and overall survival in patients with metastatic RCC according to clinical studies.","PeriodicalId":18337,"journal":{"name":"Medical alphabet","volume":" 12","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical alphabet","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33667/2078-5631-2024-7-18-25","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Every year, 400,000 new cases of renal cell carcinoma (RCC) and 175,000 deaths are registered worldwide. Currently available advanced treatments for RCC have less toxicity than previously used therapeutic agents, but drug resistance remains a clinically significant problem. Drug resistance occurs as a result of angiogenic transition through activation of pathways that do not depend on VEGF targets of most first-line treatments. Lenvatinib with everolimus can fight resistance to increase both progression-free survival and overall survival in patients with metastatic RCC according to clinical studies.
在实际临床实践中,来伐替尼和依维莫司联合治疗靶向治疗耐药的转移性肾细胞癌患者的有效性
全世界每年新增肾细胞癌(RCC)病例 40 万例,死亡病例 17.5 万例。与以前使用的治疗药物相比,目前可用的 RCC 先进疗法毒性较小,但耐药性仍然是一个严重的临床问题。耐药性的产生是由于血管生成转换途径被激活,而大多数一线治疗方法并不依赖于血管内皮生长因子靶点。根据临床研究,来伐替尼与依维莫司联合用药可以对抗耐药性,从而提高转移性RCC患者的无进展生存期和总生存期。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信